Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia

Pediatrics International

Volumn 52, Issue 5, 2010, Pages 744-748

  Yagi, Mariko ^a   Nakamura, Tsutomu ^a   Okizuka, Yo ^a   Oyazato, Yoshinobu ^a   Kawasaki, Yoko ^a   Tsuneishi, Shuichi ^a   Sakaeda, Toshiyuki ^b   Matsuo, Masafumi ^a   Okumura, Katsuhiko ^a,c   Okamura, Noboru ^d  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c HIMEJI DOKKYO UNIVERSITY   (Japan)

^d MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

carbamoyl phosphate synthase 1; epilepsy; hyperammonemia; polymorphism; valproic acid

Indexed keywords

ACETAZOLAMIDE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CARBAMOYL PHOSPHATE SYNTHASE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERAMMONEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CARBAMOYL-PHOSPHATE SYNTHASE (AMMONIA); CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; HYPERAMMONEMIA; INCIDENCE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; REFERENCE VALUES; RISK FACTORS; SEX DISTRIBUTION; VALPROIC ACID; YOUNG ADULT;

EID: 77957337146     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03157.x     Document Type: Article

References (14)

1. Guerrini R, Parmeggiani L. Practitioner review: Use of antiepileptic drugs in children. J. Child Psychol. Psychiatry 2006 47 : 115 126.
2. Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002 16 : 695 714.
3. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol. Scand. 2006 114 : 1 7.
4. Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: Looking for problems where they do not exist? Epilepsy Behav. 2007 11 : 361 366.
5. Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: Review of 14 cases in the psychiatric setting. Int. Clin. Psychopharmacol. 2007 22 : 330 337.
6. Meijer AJ, Lamers WH, Chamuleau RA. Nitrogen metabolism and ornithine cycle function. Physiol. Rev. 1990 70 : 701 748.
7. Verbiest HB, Straver JS, Colombo JP, van der Vijver JC, van Woerkom TC. Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. Acta Neurol. Scand. 1992 86 : 275 279.
8. Summar ML, Hall LD, Eeds AM et al. Characterization of genomic structure and polymorphisms in the human carbamyl phosphate synthetase I gene. Gene 2003 311 : 51 7.
9. Summar ML, Gainer JV, Pretorius M et al. Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function. Gene 2004 311 : 51 7.
10. Pearson DL, Dawling S, Walsh WF et al. Neonatal pulmonary hypertension - Urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N. Engl. J. Med. 2001 344 : 1832 1838.
11. Moonen RM, Paulussen AD, Souren NY, Kessels AG, Rubio-Gozalbo ME, Villamor E. Carbamoyl phosphate synthetase polymorphisms as a risk factor for necrotizing enterocolitis. Pediatr. Res. 2007 62 : 188 190.
12. Scolding N, Marsden CD. Metabolic disorders and the nervous system. In : Warrell DA, Cox TM, Firth JD, Benz JEJ (eds). Oxford Textbook of Medicine. Oxford University Press, Oxford, 2003 1149 1155.
13. Summar ML. Molecular genetic research into carbamoyl-phosphate synthase I: Molecular defects and linkage markers. J. Inherit. Metab. Dis. 1998 21 : 30 9.
14. Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008 49 : 1239 1276.